Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elena Caride is active.

Publication


Featured researches published by Elena Caride.


Journal of Virological Methods | 2008

Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.

Luciane P. Gaspar; Ygara S. Mendes; Anna Maya Yoshida Yamamura; Luiz F.C. Almeida; Elena Caride; Rafael B. Gonçalves; Jerson L. Silva; Andréa C. Oliveira; Ricardo Galler; Marcos da Silva Freire

The successful Yellow Fever (YF) vaccine consists of the live attenuated 17D-204 or 17DD viruses. Despite its excellent record of efficacy and safety, serious adverse events have been recorded and influenced extensive vaccination in endemic areas. Therefore, alternative strategies should be considered, which may include inactivated whole virus. High hydrostatic pressure has been described as a method for viral inactivation and vaccine development. The present study evaluated whether high hydrostatic pressure would inactivate the YF 17DD virus. YF 17DD virus was grown in Vero cells in roller bottle cultures and subjected to 310MPa for 3h at 4 degrees C. This treatment abolished YF infectivity and eliminated the ability of the virus to cause disease in mice. Pressure-inactivated virus elicited low level of neutralizing antibody titers although exhibited complete protection against an otherwise lethal challenge with 17DD virus in the murine model. The data warrant further development of pressure-inactivated vaccine against YF.


Vaccine | 2015

An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures

Renata C. Pereira; Andréa Nazaré Monteiro Rangel da Silva; Marta Cristina O. Souza; Marlon Vicente da Silva; Patrícia P.C.C. Neves; Andrea A.M.V. Silva; Denise D.C.S. Matos; Miguel Angel de la O Herrera; Anna Maya Yoshida Yamamura; Marcos da Silva Freire; Luciane P. Gaspar; Elena Caride

Yellow fever is an acute infectious disease caused by prototype virus of the genus Flavivirus. It is endemic in Africa and South America where it represents a serious public health problem causing epidemics of hemorrhagic fever with mortality rates ranging from 20% to 50%. There is no available antiviral therapy and vaccination is the primary method of disease control. Although the attenuated vaccines for yellow fever show safety and efficacy it became necessary to develop a new yellow fever vaccine due to the occurrence of rare serious adverse events, which include visceral and neurotropic diseases. The new inactivated vaccine should be safer and effective as the existing attenuated one. In the present study, the immunogenicity of an inactivated 17DD vaccine in C57BL/6 mice was evaluated. The yellow fever virus was produced by cultivation of Vero cells in bioreactors, inactivated with β-propiolactone, and adsorbed to aluminum hydroxide (alum). Mice were inoculated with inactivated 17DD vaccine containing alum adjuvant and followed by intracerebral challenge with 17DD virus. The results showed that animals receiving 3 doses of the inactivated vaccine (2 μg/dose) with alum adjuvant had neutralizing antibody titers above the cut-off of PRNT50 (Plaque Reduction Neutralization Test). In addition, animals immunized with inactivated vaccine showed survival rate of 100% after the challenge as well as animals immunized with commercial attenuated 17DD vaccine.


Anais Da Academia Brasileira De Ciencias | 2008

Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys

Gisela Freitas Trindade; Renato Sergio Marchevsky; Ana M.B. de Fillipis; Rita Maria Ribeiro Nogueira; Myrna C. Bonaldo; Pedro H. Cabello Acero; Elena Caride; Marcos da Silva Freire; Ricardo Galler

For the development of safe live attenuated flavivirus vaccines one of the main properties to be established is viral replication. We have used real-time reverse transcriptase-polymerase chain reaction and virus titration by plaque assay to determine the replication of yellow fever 17DD virus (YFV 17DD) and recombinant yellow fever 17D viruses expressing envelope proteins of dengue virus serotypes 2 and 4 (17D-DENV-2 and 17D-DENV-4). Serum samples from rhesus monkeys inoculated with YFV 17DD and 17D-DENV chimeras by intracerebral or subcutaneous route were used to determine and compare the viremia induced by these viruses. Viral load quantification in samples from monkeys inoculated by either route with YFV 17DD virus suggested a restricted capability of the virus to replicate reaching not more than 2.0 log10 PFU mL(-1) or 3.29 log10 copies mL(-1). Recombinant 17D-dengue viruses were shown by plaquing and real-time PCR to be as attenuated as YF 17DD virus with the highest mean peak titer of 1.97 log10 PFU mL(-1) or 3.53 log10 copies mL(-1). These data serve as a comparative basis for the characterization of other 17D-based live attenuated candidate vaccines against other diseases.


Virus Genes | 2008

Study of the genetic stability of measles virus CAM-70 vaccine strain after serial passages in chicken embryo fibroblasts primary cultures

Maria Beatriz Junqueira Borges; Elena Caride; Alfredo V. Jabor; José Marcus N. Malachias; Marcos da Silva Freire; Akira Homma; Ricardo Galler

To evaluate the genetic stability of the CAM-70 measles vaccine strain we have performed 10 serial passages of the seed lot virus FMS-7 in chicken embryo fibroblasts primary cultures (CEF) under production conditions. The nucleotide sequences of the seed lot virus, the virus from a vaccine vial (third passage) and from the 10th passage were determined and compared with each other and with sequences from other sources. The full genome analysis of the CAM-70 vaccine still considers it as the most divergent among all vaccine strains. The nucleotide sequence analyses of viral genomes from the three CAM-70 passage levels have demonstrated that they are identical. This study shows that the measles CAM-70 vaccine virus is highly adapted to its cultivation conditions and that its genetic stability contributes, in part, to the safety profile of the vaccine.


Vaccine | 2014

Development of a membrane adsorber based capture step for the purification of yellow fever virus.

Tânia P. Pato; Marta Cristina O. Souza; Andréa Nazaré Monteiro Rangel da Silva; Renata C. Pereira; Marlon Vicente da Silva; Elena Caride; Luciane P. Gaspar; Marcos da Silva Freire; Leda R. Castilho

Yellow fever (YF) is an endemic disease in some tropical areas of South America and Africa that presents lethality rate between 20 and 50%. There is no specific treatment and to control this disease a highly effective live-attenuated egg based vaccine is widely used for travelers and residents of areas where YF is endemic. However, recent reports of rare, sometimes fatal, adverse events post-vaccination have raised concerns. In order to increase safety records, alternative strategies should be considered, such as developing a new inactivated vaccine using a cell culture based technology, capable of meeting the demands in cases of epidemic. With this goal, the production of YF virus in Vero cells grown on microcarriers and its subsequent purification by chromatographic techniques was studied. In this work we investigate the capture step of the purification process of the YF virus. At first, virus stability was studied over a wide pH range, showing best results for the alkaline region. Considering this result and the pI of the envelope protein previously determined in silico, a strong anion exchanger was considered most suitable. Due to the easy scalability, simplicity to handle, absence of diffusional limitations and suitability for virus handling of membrane adsorbers, a Q membrane was evaluated. The amount of antigen adsorbed onto the membrane was investigated within the pH range for virus stability, and the best pH for virus adsorption was considered to be 8.5. Finally, studies on gradient and step elution allowed to determine the most adequate salt concentration for washing (0.15M) and virus elution (0.30 M). Under these operating conditions, it was shown that this capture step is quite efficient, showing high product recovery (93.2±30.3%) and efficient DNA clearance (0.9±0.3 ng/dose).


PLOS ONE | 2018

Characterization of recent and minimally passaged Brazilian dengue viruses inducing robust infection in rhesus macaques

Maria Beatriz Junqueira Borges; Renato Sergio Marchevsky; Ygara S. Mendes; Luiz Gustavo Almeida Mendes; Ana Claudia Duarte; Michael Cruz; Ana Maria Bispo de Filippis; Pedro Fernando da Costa Vasconcelos; Marcos da Silva Freire; Akira Homma; Sally P. Mossman; Edith Lepine; Yannick Vanloubbeeck; Clarisse Lorin; Marie-Pierre Malice; Elena Caride; Lucile Warter

The macaque is widely accepted as a suitable model for preclinical characterization of dengue vaccine candidates. However, the only vaccine for which both preclinical and clinical efficacy results were reported so far showed efficacy levels that were substantially different between macaques and humans. We hypothesized that this model’s predictive capacity may be improved using recent and minimally passaged dengue virus isolates, and by assessing vaccine efficacy by characterizing not only the post-dengue virus challenge viremia/RNAemia but also the associated-cytokine profile. Ten recent and minimally passaged Brazilian clinical isolates from the four dengue virus serotypes were tested for their infectivity in rhesus macaques. For the strains showing robust replication capacity, the associated-changes in soluble mediator levels, and the elicited dengue virus-neutralizing antibody responses, were also characterized. Three isolates from dengue virus serotypes 1, 2 and 4 induced viremia of high magnitude and longer duration relative to previously reported viremia kinetics in this model, and robust dengue virus-neutralizing antibody responses. Consistent with observations in humans, increased MCP-1, IFN-γ and VEGF-A levels, and transiently decreased IL-8 levels were detected after infection with the selected isolates. These results may contribute to establishing a dengue macaque model showing a higher predictability for vaccine efficacy in humans.


Virus Research | 2008

Evidence for interferon production and its correlation with YF 17DD vaccine virus yields in primary chick embryo cells.

Elena Caride; Maria Beatriz Junqueira Borges; Rugimar Marcovistz; Ricardo Galler; Marcos da Silva Freire


American Journal of Tropical Medicine and Hygiene | 2017

Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models

Stephen Tottey; Yoko Shoji; R. Mark Jones; Jessica A. Chichester; Brian J. Green; Konstantin Musiychuk; Huaxin Si; Slobodanka Manceva; Amy Rhee; Moneim Shamloul; Joey Norikane; Rosane Cuber Guimarães; Elena Caride; Andréa Nazaré Monteiro Rangel da Silva; Marisol Simões; Patrícia Cristina da Costa Neves; Renato Sergio Marchevsky; Marcos da Silva Freire; Stephen J. Streatfield; Vidadi Yusibov


Archive | 2017

Avaliação das condições de inativação do vírus Zika por β-Propiolactona e das metodologias do processo

Marta Cristina de Oliveira Souza; Mariana Pierre de Barros Gomes; Liliane Monteiro de Morais; Gisela Freitas Trindade; André da Silva Tavares; Luiz Gustavo Almeida Mendes; Sheila Maria Barbosa de Lima; Elena Caride; Marcia Archer da Motta


Archive | 2017

Análises estratégicas para minimizar reação cruzada em Teste de Neutralização por Redução de Placas de Lise do vírus da ZIKA

Stephanie Almeida da Silva; José Henrique Rezende Linhares; Vanessa de Oliveira Santos; Emily Hime Miranda; Kátia Paulino Ribeiro de Souza; Felipe Soares Figueiredo; Márcia Archer da Motta; Elena Caride; Marcos da Silva Freire; Sheila Maria Barbosa de Lima

Collaboration


Dive into the Elena Caride's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marta Cristina de Oliveira Souza

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Akira Homma

Oswaldo Cruz Foundation

View shared research outputs
Researchain Logo
Decentralizing Knowledge